UK markets closed
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • FTSE 250

    22,646.08
    -38.76 (-0.17%)
     
  • AIM

    1,182.30
    -6.44 (-0.54%)
     
  • GBP/EUR

    1.1690
    -0.0076 (-0.65%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.50%)
     
  • BTC-GBP

    37,269.46
    +523.82 (+1.43%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • DOW

    34,580.08
    -59.71 (-0.17%)
     
  • CRUDE OIL

    66.22
    -0.28 (-0.42%)
     
  • GOLD FUTURES

    1,782.10
    +21.40 (+1.22%)
     
  • NIKKEI 225

    28,029.57
    +276.20 (+1.00%)
     
  • HANG SENG

    23,766.69
    -22.24 (-0.09%)
     
  • DAX

    15,169.98
    -93.13 (-0.61%)
     
  • CAC 40

    6,765.52
    -30.23 (-0.44%)
     

Outlook on the Investigational New Drug CDMO Global Market to 2028 - Size, Share & Trends Analysis Report

·10-min read

Dublin, Nov. 02, 2021 (GLOBE NEWSWIRE) -- The "Investigational New Drug CDMO Market Size, Share & Trends Analysis Report By Product (Small Molecule, Large Molecule), By Service (Contract Development, Contract Manufacturing), By End User, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

The global investigational new drug CDMO market size is expected to reach USD 6.8 billion by 2028, according to a new report by the publisher It is expected to expand at a CAGR of 6.9% from 2021 to 2028. This is largely due to the increased R&D investments, along with stringent regulations pertaining to IND.

The U.S. FDA and the European Medicines Agency (EMA) are health authority bodies that regulate the use of investigational drugs in the U.S. and the European Union, respectively. In addition, investigational review boards (IRBs) in the U.S. and ethics committees (ECs) in the European Union must approve the use of drugs in humans.

It is the requirement of a federal law that a drug be the subject of an approved marketing application prior to it is distributed or transported across the state lines. Hence, sponsors aiming to conduct clinical studies that involve an IND should gain exemption from the FDA to permit the shipping of the investigational drug to clinical investigators in several states.

The pandemic has significantly impacted the global economy in 2020 and has an ongoing impact on various industries. However, the market for IND CDMO has benefited from the pandemic. Prior to COVID-19, prospective sponsors demanded facility audits to ensure CDMOs had the required capacity, equipment, and personnel to undertake their projects. Nowadays, CDMOs should find new ways to attract new sponsors, such as through videos, virtual reality, and other technologies that allow sponsors to virtually experience the site.

Investigational New Drug CDMO Market Report Highlights

  • In terms of product, the small molecule segment dominated the market with a revenue share of 89.0% in 2020. This is largely due to the increasing number of small molecules in development. Besides, in 2019, the small molecules dominated the new drug approvals accounting for 79% of all the NME approvals

  • Based on service, the contract development segment led the market with a revenue share of 85.5% in 2020. The contract development offers several benefits over in-house development of drugs, such as access to industry experts, less time to market, cost-effectiveness, and more focus on core competencies

  • By end user, pharmaceutical companies accounted for the largest share of 69.4% in 2020. This is due to the changes in the pharmaceutical industry that have an impact on research and development strategies, which, in turn, influence new drug approval trends

  • Asia Pacific to register the fastest growth rate of 7.7% over the forecast period. Due to the rapid growth of pharmaceutical firms and contract manufacturing organizations in developing countries, such as India and China, the region is likely to overtake Europe and North America in the near future

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Global IND CDMO Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increasing outsourcing services by pharmaceutical companies
3.2.1.2 Rising investment in R&D
3.2.1.3 Growing pharmaceutical industry
3.2.1.5 Stringent regulatory requirements
3.2.2 Market Restraint Analysis
3.2.2.1 Compliance issues while outsourcing
3.2.2.2 Changing scenario in developing countries
3.3 Penetration & Growth Prospect Mapping
3.4 COVID-19 Impact on the Market
3.5 Major Deals and Strategic Alliances Analysis
3.6 Global IND CDMO: Market Analysis Tools
3.6.1 Industry Analysis - Porter's
3.6.3 PESTEL Analysis

Chapter 4 Global IND CDMO Market: Product Segment Analysis
4.1 Global IND CDMO Market: Product Market Share Analysis, 2020 & 2028
4.2 Small Molecule
4.2.1 Small Molecule Market, 2016 - 2028 (USD Million)
4.3 Large Molecule
4.3.1 Large Molecule Market, 2016 - 2028 (USD Million)

Chapter 5 Global IND CDMO Market: Service Segment Analysis
5.1 Global IND CDMO Market: Service Market Share Analysis, 2020 & 2028
5.2 Contract Development
5.2.1 Contract Development market, 2016 - 2028 (USD Million)
5.2.2 Small Molecule
5.2.2.1 Small Molecule market, 2016 - 2028 (USD Million)
5.2.2.2.1 Bioanalysis and DMPK studies
5.2.2.2.2 Bioanalysis and DMPK studies market, 2016 - 2028 (USD Million)
5.2.2.2.3 Toxicology Testing
5.2.2.2.4 Toxicology Testing market, 2016 - 2028 (USD Million)
5.2.2.2.5 Pathology and safety pharmacology studies
5.2.2.2.6 Pathology and safety pharmacology studies market, 2016 - 2028 (USD Million)
5.2.2.2.7 Drug substance synthetic route development
5.2.2.2.8 Drug substance synthetic route development market, 2016 - 2028 (USD Million)
5.2.2.2.9 Drug substance process development
5.2.2.2.10 Drug substance process development market, 2016 - 2028 (USD Million)
5.2.2.2.11 Drug substance synthetic route development
5.2.2.2.12 Drug substance synthetic route development market, 2016 - 2028 (USD Million)
5.2.2.2.13 Form selection crystallization process development
5.2.2.2.14 Form selection crystallization process development market, 2016 - 2028 (USD Million)
5.2.2.2.15 Scale up of drug substance
5.2.2.2.16 Scale up of drug substance market, 2016 - 2028 (USD Million)
5.2.2.2.17 Preformulation
5.2.2.2.18 Preformulation market, 2016 - 2028 (USD Million)
5.2.2.2.19 Preclinical formulation selection
5.2.2.2.20 Preclinical formulation selection market, 2016 - 2028 (USD Million)
5.2.2.2.21 First in Man Formulation/ Process Development
5.2.2.2.22 First in Man Formulation/ Process Development market, 2016 - 2028 (USD Million)
5.2.2.2.23 Analytical method development / validation
5.2.2.2.24 Analytical method development / validation market, 2016 - 2028 (USD Million)
5.2.2.2.25 Release testing of drug substance and drug product
5.2.2.2.25 Release testing of drug substance and drug product market, 2016 - 2028 (USD Million)
5.2.2.2.26 Work up Purification Steps
5.2.2.2.27 Work up purification steps market, 2016 - 2028 (USD Million)
5.2.2.2.28 Telescoping & Process Refining
5.2.2.2.29 Telescoping & Process Refining market, 2016 - 2028 (USD Million)
5.2.2.2.30 Initial Optimization
5.2.2.2.31 Initial Optimization market, 2016 - 2028 (USD Million)
5.2.2.2.32 Formal stability of drug substance and drug product
5.2.2.2.33 Formal stability of drug substance and drug product market, 2016 - 2028 (USD Million)
5.2.3 Large Molecule
5.2.3.1 Large Molecule market, 2016 - 2028 (USD Million)
5.2.3.2 Cell Line development
5.2.3.3 Cell line development market, 2016 - 2028 (USD Million)
5.2.3.4 Process development
5.2.3.5 Process development market, 2016 - 2028 (USD Million)
5.2.3.4.1 Upstream
5.2.3.4.1.1 Upstream market, 2016 - 2028 (USD Million)
5.2.3.4.1.2 Microbial
5.2.3.4.1.3 Microbial market, 2016 - 2028 (USD Million)
5.2.3.4.1.4 Mammalian
5.2.3.4.1.5 Mammalian market, 2016 - 2028 (USD Million)
5.2.3.4.1.6 Others
5.2.3.4.1.7 Others market, 2016 - 2028 (USD Million)
5.2.3.4.1.8 Upstream
5.2.3.4.1.9 Upstream market, 2016 - 2028 (USD Million)
5.2.3.4.2 Downstream
5.2.3.4.2.1 Downstream market, 2016 - 2028 (USD Million)
5.2.3.4.2.2 MABs
5.2.3.4.2.3 MABs market, 2016 - 2028 (USD Million)
5.2.3.4.2.4 Recombinant Proteins
5.2.3.4.2.5 Recombinant Proteins market, 2016 - 2028 (USD Million)
5.2.3.4.2.6 Others
5.2.3.4.2.7 Others market, 2016 - 2028 (USD Million)
5.3 Contract Manufacturing
5.3.1 Contract Manufacturing market, 2016 - 2028 (USD Million)
5.3.1.1 Small Molecule
5.3.1.2 Small Molecule market, 2016 - 2028 (USD Million)
5.3.1.1.1 Oral Solids
5.3.1.1.2 Oral Solids market, 2016 - 2028 (USD Million)
5.3.1.1.1 Liquid & Semi-solids
5.3.1.1.2 Liquid & Semi-solids market, 2016 - 2028 (USD Million)
5.3.1.1.3 InjecTables
5.3.1.1.4 InjecTables market, 2016 - 2028 (USD Million)
5.3.1.1.5 Others
5.3.1.1.6 Others market, 2016 - 2028 (USD Million)
5.3.2 Large Molecule
5.3.2.1 Large Molecule market, 2016 - 2028 (USD Million)
5.3.2.1.1 MABs
5.3.2.1.2 MABs market, 2016 - 2028 (USD Million)
5.3.2.1.3 Recombinant Proteins
5.3.2.1.4 Recombinant Proteins market, 2016 - 2028 (USD Million)
5.3.2.1.5 MABs
5.3.2.1.6 MABs market, 2016 - 2028 (USD Million)
5.3.2.1.7 Others
5.3.2.1.8 Others market, 2016 - 2028 (USD Million)

Chapter 6 Global IND CDMO Market: End-user Segment Analysis
6.1 Global IND CDMO Market: End-user Market Share Analysis, 2020 & 2028
6.2 Pharmaceutical Companies
6.2.1 Pharmaceutical companies IND CDMO Market, 2016 - 2028 (USD Million)
6.3 Biotech
6.3.2. Biotech Companies IND CDMO Market, 2016 - 2028 (USD Million)
6.4 Others
6.4.2. Others IND CDMO Market, 2016 - 2028 (USD Million)

Chapter 7 Global IND CDMO Market: Regional Analysis

Chapter 8 Company Profiles
8.1 Catalent, Inc.
8.1.1 Company Overview
8.1.2 Service Benchmarking
8.1.3 Financial Performance
8.1.4 Strategic Initiatives
8.2 Lonza
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Service Benchmarking
8.2.5 Strategic Initiatives
8.3 Recipharm AB
8.3.1 Company Overview
8.3.2 Service Benchmarking
8.3.3 Strategic Initiatives
8.4 Siegfried Holding AG
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Service Benchmarking
8.5 Patheon Inc.
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Service Benchmarking
8.6 Covance
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Service Benchmarking
8.7 IQVIA Holdings Inc.
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Service Benchmarking
8.7.4 Strategic Initiatives
8.8 Cambrex Corporation
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Service Benchmarking
8.9 Charles River Laboratories International, Inc.
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Service Benchmarking
8.9.4 Strategic Initiatives
8.10 Syneous Health
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Service Benchmarking
8.10.4 Strategic Initiatives

For more information about this report visit https://www.researchandmarkets.com/r/1fmfvn

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting